title: N-Methyl-D-Aspartate Receptors, Ketamine, and Rett Syndrome: Something Special on the Road to Treatments?
authors.affiliation: Departments of Neurosciences and Psychiatry, Case Western Reserve University School of Medicine, Cleveland, Ohio. Electronic address: david.katz@case.edu.
authors.forename: David M
authors.initials: DM
authors.lastname: Katz
authors.affiliation: MindImmune Therapeutics (FSM), Kingston, Rhode Island.
authors.forename: Frank S
authors.initials: FS
authors.lastname: Menniti
authors.affiliation: Neuroscience Innovative Medicines and Early Development Biotech Unit (RJM), AstraZeneca, Cambridge, Massachusetts.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Mather
mesh_terms: D018691:Excitatory Amino Acid Antagonists; D006801:Humans; D007649:Ketamine; D016202:N-Methylaspartate; D016194:Receptors, N-Methyl-D-Aspartate; D015518:Rett Syndrome; D013116:Spinal Cord
chemical_list: D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D016202:N-Methylaspartate; D007649:Ketamine